DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04529278

LIRADIAL

UnknownPhase 2

Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

4

Recruiting sites

—

Enrollment

18

actual

Study population

Chronic kidney disease, Obesity / overweight, Renal impairment, Type 2 diabetes

Key I/E criterion

•BMI ≥30

Primary endpoint

•Weight Loss

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04529278
Org study IDLIRADIAL

Timeline

Milestones

Study first posted2020-08-27actual
Study start2021-01-18actual
Primary completion2023-01-17actual
Last update posted2023-04-14actual
Study completion2023-12-31estimated

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Chronic kidney diseaseObesity / overweightRenal impairmentType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Patient aged ≥ 18 and <70
•Patient on hemodialysis for more than 6 months
•Type 2 diabetic patient
•Patient with a BMI> 30 kg / m2 with a Temporary Contraindication for kidney transplant for renal transplant due to overweight by his graft center
•Patient affiliated to a health insurance plan
•French speaking patient
•Patient having given free, informed and written consent

Exclusion criteria

•Patient with a Temporary Contraindication for kidney transplant for a cause other than overweight
•Patient with personal or family history of thyroid medullary cancer
•Patient with a history of acute or chronic pancreatitis
•Patient who has already had hypersensitivity to liraglutide (or to any other component of the product)
•Patient who has already had a severe digestive intolerance to taking GLP-1 receptor agonists (such as exenatide or lixisenatide)
•Patient already included in an interventional risk research protocol (RIPH1)
•Pregnant or lactating woman
•Patient under guardianship or curatorship
•Patient deprived of liberty

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
3
Weight & body composition
2
Glycemic / diabetes
2
Other clinical outcomes
1

Weight & body composition

2 endpoints
Primary/protocol endpoint

Weight Loss at Week 26

Time frame:Week 26

change from baseline, improvement

Secondary/protocol endpoint

Evolution of weight

Time frame:Week 26

Total fat mass

change from baseline, improvement

Glycemic / diabetes

2 endpoints
Secondary/protocol endpoint/low confidence

Regulation of blood sugar

Time frame:Week 26

descriptive, improvement

Secondary/protocol endpoint

Glycemic balance

Time frame:Week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Safety / tolerability / PK

3 endpoints
Secondary/protocol endpoint

Tolerance of luraglutide

Time frame:Week 26

Treatment-emergent AEs (any)

event count, event

Secondary/protocol endpoint

Hypoglycemia

Time frame:Week 26

event count, event

Secondary/protocol endpoint

Therapeutic monitoring

Time frame:Week 26

Plasma concentration (steady state)

concentration, descriptive

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint/low confidence

Lift of CIT for transplant for obesity

Time frame:Week 26

categorical status, improvement

Publications (12)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.